Fenwick represents Augmedix, a company specializing in providing remote medical documentation and live clinical support services, in its $25 million private placement financing and completion of a reverse merger with Malo Holdings Corp., an SEC-reporting public Delaware corporation. Following the transaction, the merged entity will be named "Augmedix, Inc.," and will continue the historic and innovative business of Augmedix.
In connection with the financing, current investors Redmile Group, DCM, and McKesson Ventures invested alongside new investors. Financial advisory firms, Stifel, Nicolaus & Company, Incorporated, B. Riley Securities, Inc., and GP Nurmenkari, Inc. (as consulted by Intuitive Venture Partners) acted as placement agents for the private placement. Montrose Capital Partners was the sponsor for this transaction.
More information about the financing and reverse merger can be obtained from Augmedix’s announcement.
The Fenwick transaction team included corporate partners Michael Esquivel, Ethan Skerry and Robert Freedman; counsel Nicolas Dumont and associates Victoria Lupu, Nam Kim, Meredith Evancie, Nikhil Sharma, Joshua Fuller, Adam Conway and Jamal Johnson; as well as executive compensation & employee benefits partner Matthew Cantor and counsel Nicholas Frey.